Artisan Small Cap Fund Sold Insmed (INSM) on Valuation Consideration

1 hour ago 2

Soumya Eswaran

Tue, March 17, 2026 astatine 9:32 AM CDT 3 min read

Artisan Partners, an concern absorption company, released its fourth-quarter 2025 capitalist missive for “Artisan Small Cap Fund”. A transcript of the missive tin beryllium downloaded here. The Fund seeks to put successful companies that person franchise characteristics, with beardown net trajectories, and are trading astatine a discount to the estimated backstage marketplace value. Despite beardown results successful 2025, volatility was elevated, and sentiment shifted frequently, influenced by governmental developments successful the US, evolving commercialized argumentation rhetoric, changing expectations for monetary policy, and ongoing geopolitical tensions. Against this backdrop, the Fund posted beardown implicit returns successful the 4th quarter, outperforming some the Russell 2000® Growth Index and the Russell 2000® Index. The portfolio delivered beardown results successful the 4th crossed each segments. In contrast, for the afloat year, the Fund generated beardown results but trailed some the indexes. In Q4 2025, the marketplace enactment shifted backmost to companies with durable nett cycles. Moving to 2026, the steadfast continues to absorption connected its proven method of identifying nett cycles successful franchise companies astatine tenable valuations. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Artisan Small Cap Fund highlighted Insmed Incorporated (NASDAQ:INSM) arsenic 1 of its starring contributors. Insmed Incorporated (NASDAQ:INSM) is simply a biopharmaceutical institution focusing connected processing therapies for patients with superior and uncommon diseases. On March 16, 2026, Insmed Incorporated (NASDAQ:INSM) banal closed astatine $144.60 per share. One-month instrumentality of Insmed Incorporated (NASDAQ:INSM) was -3.93%, and its shares gained 87.82% implicit the past 52 weeks. Insmed Incorporated (NASDAQ:INSM) has a marketplace capitalization of $31.17 billion.

Artisan Small Cap Fund stated the pursuing regarding Insmed Incorporated (NASDAQ:INSM) successful its 4th fourth 2025 capitalist letter:

"Our apical contributors successful Q4 were MACOM Technology Solutions, Insmed Incorporated (NASDAQ:INSM) and Vita Coco. Insmed is simply a biotechnology institution focused connected pulmonary diseases. We exited our presumption during the 4th owed to marketplace headdress considerations, though the banal remained a apical performer. Its spot was driven by the palmy motorboat of Brinsupri™ (brensocatib), the archetypal approved therapy for non-cystic fibrosis bronchiectasis, which generated $28 cardinal successful archetypal income from astir 2,500 patients and 1,700 prescribers, on with a robust pipeline of further imaginable therapies."

Read Entire Article